Developing next generation kinase inhibitors for autoimmune disease & cancer.
*Molecular structure of TYK2 kinase (blue) and a prototype inhibitor (gold)
SCROLL DOWN
Welcome to Sareum.
Sareum is a clinical-stage small molecule company actively involved in developing next-generation kinase inhibitors to treat autoimmune diseases and cancer.
We recognise the crucial role of the TYK/JAK kinase cell signalling family in maintaining a healthy immune system, and our pipeline is primarily focused on this area of scientific and commercial interest.
About
Sareum.
We are committed to advancing molecules in the TYK2/JAK1 space. Our focus on this dual JAK kinase inhibition is due to the potential superior efficacy we believe this offers compared to agents targeting just one of these kinases.
Research &
development.
We are focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential.
Investor
relations.
View our share price, latest results and reports, regulatory news and sign up to email alerts.
Latest developments.
Autoimmune – TYK2/JAK1 kinases
Cancer – TYK2/JAK1 kinases
TYK2/JAK1 – Viral Infections
Cancer – Chk1 kinase
Company highlight.
“Sareum has made solid progress, most notably with the restart of the Phase 2-enabling toxicology programme for SDC-1801, our lead asset. This programme is central to advancing SDC-1801 into Phase 2 development and we are encouraged by the immediate progress”
Stephen Parker PhD – Executive Chairman
